Postoperative surveillance of pancreatic cancer patients
- PMID: 31204168
- DOI: 10.1016/j.ejso.2019.05.031
Postoperative surveillance of pancreatic cancer patients
Abstract
Background: The aim of this study is to collect the best available evidence for diagnostic modalities, frequency, and duration of surveillance after resection for pancreatic ductal adenocarcinoma (PDAC).
Methods: PDAC guidelines published after 2015 were collected. Furthermore, a systematic search of the literature on postoperative surveillance was performed in PubMed and Embase from 2000 to 2019. Articles comparing different diagnostic modalities and frequencies of postoperative surveillance in PDAC patients with regard to survival, quality of life, morbidity and cost-effectiveness were selected.
Results: The literature search resulted in 570 articles. A total of seven guidelines and twelve original clinical studies were eventually evaluated. PDAC guidelines increasingly recommend a combination of tumor marker testing and computed tomography (CT) imaging every three to six months during the first two years after resection. These guidelines are, however, based on expert opinion and other low-level evidence. Prospective studies comparing different surveillance strategies are lacking. According to recent studies, surveillance with tumor markers and imaging at regular intervals results in the detection of PDAC recurrence before the onset of symptoms and more frequent administration of further therapy, such as chemotherapy or radiotherapy.
Conclusion: Current evidence for recurrence-focused surveillance after PDAC resection is limited and contradictory. Consequently, recommendations on surveillance are conflicting. To define the clinical merit of recurrence-focused surveillance, patients who are most likely to benefit from early detection and treatment of PDAC recurrence need to be identified. To this purpose, well-designed prospective studies are needed, accounting for both economical and psychosocial implications of surveillance.
Keywords: Follow-up; Pancreatectomy; Pancreatic cancer; Postoperative surveillance; Recurrence; Systematic review.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Similar articles
-
Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design.Trials. 2024 Jun 20;25(1):401. doi: 10.1186/s13063-024-08223-5. Trials. 2024. PMID: 38902836 Free PMC article.
-
Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.JAMA Surg. 2019 Jun 1;154(6):e190484. doi: 10.1001/jamasurg.2019.0484. Epub 2019 Jun 19. JAMA Surg. 2019. PMID: 30942874 Free PMC article.
-
The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.BMC Surg. 2015 Nov 28;15:123. doi: 10.1186/s12893-015-0110-5. BMC Surg. 2015. PMID: 26615588 Free PMC article.
-
Meta-analysis of recurrence pattern after resection for pancreatic cancer.Br J Surg. 2019 Nov;106(12):1590-1601. doi: 10.1002/bjs.11295. Epub 2019 Aug 27. Br J Surg. 2019. PMID: 31454073
-
What is the Value of Total Mesopancreas Excision in Pancreatic Ductal Adenocarcinoma? Current Evidence of the Literature.Chirurgia (Bucur). 2018 May-Jun;113(3):335-343. doi: 10.21614/chirurgia.113.3.335. Chirurgia (Bucur). 2018. PMID: 29981664 Review.
Cited by
-
The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy.Cancers (Basel). 2022 Jan 3;14(1):217. doi: 10.3390/cancers14010217. Cancers (Basel). 2022. PMID: 35008381 Free PMC article. Review.
-
Propofol-based intravenous anesthesia is associated with better survival than desflurane anesthesia in pancreatic cancer surgery.PLoS One. 2020 May 21;15(5):e0233598. doi: 10.1371/journal.pone.0233598. eCollection 2020. PLoS One. 2020. PMID: 32437450 Free PMC article.
-
Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer.J Clin Med. 2019 Jul 27;8(8):1115. doi: 10.3390/jcm8081115. J Clin Med. 2019. PMID: 31357636 Free PMC article.
-
Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.Ann Surg Oncol. 2023 Oct;30(11):6652-6660. doi: 10.1245/s10434-023-13701-2. Epub 2023 Jun 11. Ann Surg Oncol. 2023. PMID: 37303025
-
Impact of Structured Postoperative Surveillance on Survival in Patients with Resected Pancreatic Adenocarcinoma.Cancers (Basel). 2025 Apr 24;17(9):1424. doi: 10.3390/cancers17091424. Cancers (Basel). 2025. PMID: 40361350 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical